Anifrolumab-fnia (Saphnelo™)

Covered: anifrolumab‑fnia (Saphnelo) 300 mg IV every 4 weeks for adults (≥18) with moderate‑to‑severe, autoantibody‑positive SLE who are receiving standard therapy (or have documented intolerance); seronegative patients and those <18 are excluded. Key requirements: prescribed by or in consultation with a rheumatologist, clinical immunologist, nephrologist, neurologist, or dermatologist; initial approval 6 months (renewal 12 months) with documentation of diagnosis and autoantibody positivity, concurrent standard therapy (or intolerance), dosing/administration records, and demonstrated clinical response for reauthorization.

"Treatment of adult patients (≥18 years) with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy (FDA-approved indication)."

Sign up to see full coverage criteria, indications, and limitations.